Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Own The Gas Pump, And Collect 8% Yields
10:30am, Saturday, 29'th Mar 2025
I love topping off my gas tank; I get to see all the people who pay for my retirement in action. Sometimes, it's the most overlooked aspects of life that can pay you the most income! My Income Method
GLP-1 space will remain two player over the medium to long term, says Mizuho's Jared Holz
06:21pm, Friday, 28'th Mar 2025
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to talk Novo Nordisk sinking on lighter-than-expected GLP-1 demand.
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
09:15am, Thursday, 27'th Mar 2025
Over the last couple of years, the pharmaceutical sector has captivated investors thanks in large part to novel medications used to treat chronic weight management and diabetes.
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e –
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
08:40am, Wednesday, 26'th Mar 2025
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a dev
Structure Therapeutics CEO on latest GLP-1 developments
06:26pm, Monday, 24'th Mar 2025
Ray Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk advancements in weight loss drugs and the development of a GLP-1 pill.
Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
09:28am, Thursday, 20'th Mar 2025
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, al
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
08:46am, Tuesday, 18'th Mar 2025
When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off-label use by celebrities and social media influencers for cutting weight b
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therap
ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug impla
Giftify, Inc. Reports Surge in Pharmacy Retailer Gift Card Demand Following GLP-1 Medication Savings Initiative
08:30am, Wednesday, 12'th Mar 2025
Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving Solutions Surge Driven by Ozempic and Zepbound Prescription Savings Opportunities Combined with Seasonal Health Produ
RoadFlex Announces Strategic Fuel Partnership with Global Partners, a Leader in Energy Solutions
11:00am, Tuesday, 11'th Mar 2025
WALTHAM, Mass.--(BUSINESS WIRE)-- #roadflex--RoadFlex, the leader in fuel risk management and fleet card solution, today announced a new strategic partnership with Global Partners LP (NYSE: GLP). This
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
11:03am, Monday, 10'th Mar 2025
Novo Nordisk A/S NYSE: NVO has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug Admini
Teladoc Health Adds GLP-1 Self-Pay Option to Comprehensive Weight Care
08:31am, Thursday, 06'th Mar 2025
Pharmacy Integration with Gifthealth to Extend Seamless Support for FDA-Approved Medication to Obesity Program Members Without GLP-1 Coverage Pharmacy Integration with Gifthealth to Extend Seamless Su
Novo Nordisk to explore how GLP-1 drugs can help patients with addiction
04:28am, Thursday, 06'th Mar 2025
Novo Nordisk will explore how GLP-1 drugs potentially could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.
